SlideShare a Scribd company logo
1 of 17
GCURS 2016
“The effect of modified PEG and GP100
on AuNV induced IL-12 production”
Ángel A. Garcés, Emily Reiser Evans, Rebekah Drezek
Drezek Lab
October 22, 2016
What is cancer immunotherapy?
• Immune system recognizes foreign entities as harmful
• After recognition, cytotoxic T-cells attack the entity and destroy it
• Cancer cells difficult to recognize as foreign in the body
• Retrain body to recognize cancer tumors and destroy them
• Components of a successful vaccine: antigen and adjuvant
Project Introduction
• Developing gold nanoparticle (AuNP) vaccines (AuNV) for cancer
immunotherapy applications in vitro in BMDCs
• Specific antigen overexpressed in mouse melanoma tumors
conjugated to AuNP induces immune response
• Optimize the design of AuNVs for maximum effectiveness in vitro
Specific project goals
• To modify the GP100 peptide by replacing the terminal leucine
residue with an aromatic one to induce a strong immune response
• To quantify the immune response via IL-12 p70 ELISA
Previous literature
• Yang et. Al (2011): Aromatic amino acids conjugated to the end of
AuNPs found to increase AuNV cellular uptake in vitro
• Xia et. Al (2012): IL-12 crucial to maturation of CD8+ T-cells
• Almeida et. Al (2015): AuNVs developed elicit successful immune
responses in vivo via proof of concept antigen
AuNV
CD4+
AuNV activates
APC
CD8+
CD4+ recruits CD8+
cytotoxic T-cells
Melanoma
Tumor
APC
IL-12 cytokine
secretion
IL-12
Figure 1: Overview of AuNV immunology
Antigen presenting cells (APCs), which represent either J774.A macrophages or BMDCs, produce
cytokines to communicate with T-cells to coordinate an immune response. The more cytokines
produced correlates to a stronger immune response.
Modifying the GP100 peptide
• Preliminary results: AuNP-PEG-GP100 showed highest induced IL-12 cytokine
production in J774.A macrophages
• GP100 had stronger immune response than other melanoma associated antigens
• Unmodified GP100: KVPRNQDWL
• Replaced end amino acid (“L”) with an aromatic amino acid
Figure 2: Unmodified GP100 peptide structure
The terminal Leucine has been highlighted for emphasis.
GP100 Variant Amino Acid Sequence
GP100 (Normal) KVPRNQDWL
GP100 (W) KVPRNQDWW
GP100 (Y) KVPRNQDWY
GP100 (F) KVPRNQDWF
GP100 (-L) KVPRNQDW-
Table of GP100 variant sequences
Methods
Results of preliminary ELISA testing
-100
0
100
200
300
400
500
600
700
PBS AuNP-PEG (COOH) AuNP-PEG-GP100
(normal)
AuNP-PEG-GP100
(W)
AuNP-PEG-GP100
(Y)
AuNP-PEG-GP100
(F)
AuNP-PEG-GP100
(-L)
LPS
IL-12concentration(pg/mL)
Preliminary AuNV induced IL-12 production observed in BMDCs in vitro
Results of secondary ELISA testing
0
50
100
150
200
250
300
IL-12concentration(pg/mL)
Secondary AuNV induced IL-12 production in vitro in BMDCs
ELISA data analysis
• Preliminary/secondary ELISA shows a significant immune response for
PEGylated and GP100 variants
• No discernable advantage to conjugating AuNVs with terminal
aromatic residues; no discernable effect on IL-12 production
• AuNP-PEG (COOH) induced higher IL-12 production than AuNP-mPEG
• Terminal aromatic residues had no discernable effect on IL-12
production in BMDCs
AuNP-PEG (COOH) vs. AuNP-mPEG
AuNP
AuNP
Possible advantages to AuNP-PEG (COOH)
• COO- group (at pH 7.4) is more hydrophilic than methyl group
• PEG (COOH) has a net negative charge at physiological pH
• Possibility for nucleophilic substitution to make covalent bonds arises
• Kumar (2012): Covalent coupling to biological molecules
• PEG (COOH) has a COO- similar to a C-terminus on proteins
Conclusions
• Terminal aromatic residues on AuNVs do not increase IL-12
production in BMDCs
• Ability of AuNP-PEG (COOH) to covalently interact with cell receptors
increases its applications for treating cancer
Future directions
• Further ELISA testing further confirm presence of PEG effects
• Flow cytometry with anti-CD40, anti-CD86, and anti-CD80 cell surface
markers to more accurately quantify immune response (paper?)
Questions?

More Related Content

Similar to GCURS Presentation

Validation of anti niv igm capture elisa version#1
Validation of anti niv igm capture elisa version#1Validation of anti niv igm capture elisa version#1
Validation of anti niv igm capture elisa version#1krishgen
 
Chimeric virus like particles made using GAG and M1 Capsid prteins providing ...
Chimeric virus like particles made using GAG and M1 Capsid prteins providing ...Chimeric virus like particles made using GAG and M1 Capsid prteins providing ...
Chimeric virus like particles made using GAG and M1 Capsid prteins providing ...Aditya S Kulkarni
 
BIOTECHNOLOGICAL APPLICATIONS 1Therapeutic antibodies 6_humanization
BIOTECHNOLOGICAL APPLICATIONS 1Therapeutic antibodies 6_humanizationBIOTECHNOLOGICAL APPLICATIONS 1Therapeutic antibodies 6_humanization
BIOTECHNOLOGICAL APPLICATIONS 1Therapeutic antibodies 6_humanizationFREE EDUCATION FOR ALL
 
OPG ELISA Assay Publication
OPG ELISA Assay PublicationOPG ELISA Assay Publication
OPG ELISA Assay PublicationNihal Sarikaya
 
Antibody Customer Review For Tau Polyclonal Antibody (STJ95911)
Antibody Customer Review For Tau Polyclonal Antibody (STJ95911)Antibody Customer Review For Tau Polyclonal Antibody (STJ95911)
Antibody Customer Review For Tau Polyclonal Antibody (STJ95911)St John's Laboratory Ltd
 
Lynch CERCA Poster S16 [4196]
Lynch CERCA Poster S16 [4196]Lynch CERCA Poster S16 [4196]
Lynch CERCA Poster S16 [4196]Andrew Lynch
 
Melanoma and Parkinson disease & Link between them.
Melanoma and Parkinson disease &  Link between them.Melanoma and Parkinson disease &  Link between them.
Melanoma and Parkinson disease & Link between them.SAKEEL AHMED
 
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassaysMichael A. Lomotan
 
Presentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014Presentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014St John's Laboratory Ltd
 
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchangeStructural basis of omalizumab therapy and omalizumab-mediated IgE exchange
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchangeGul Muneer
 
Replacement Polymorphism of DENV E Asn-67 with Lys-67
Replacement Polymorphism of DENV E Asn-67 with Lys-67Replacement Polymorphism of DENV E Asn-67 with Lys-67
Replacement Polymorphism of DENV E Asn-67 with Lys-67vivishout
 

Similar to GCURS Presentation (20)

Validation of anti niv igm capture elisa version#1
Validation of anti niv igm capture elisa version#1Validation of anti niv igm capture elisa version#1
Validation of anti niv igm capture elisa version#1
 
Nc3R\'s Meeting
Nc3R\'s MeetingNc3R\'s Meeting
Nc3R\'s Meeting
 
MMRIResearch
MMRIResearchMMRIResearch
MMRIResearch
 
Chimeric virus like particles made using GAG and M1 Capsid prteins providing ...
Chimeric virus like particles made using GAG and M1 Capsid prteins providing ...Chimeric virus like particles made using GAG and M1 Capsid prteins providing ...
Chimeric virus like particles made using GAG and M1 Capsid prteins providing ...
 
BIOTECHNOLOGICAL APPLICATIONS 1Therapeutic antibodies 6_humanization
BIOTECHNOLOGICAL APPLICATIONS 1Therapeutic antibodies 6_humanizationBIOTECHNOLOGICAL APPLICATIONS 1Therapeutic antibodies 6_humanization
BIOTECHNOLOGICAL APPLICATIONS 1Therapeutic antibodies 6_humanization
 
OPG ELISA Assay Publication
OPG ELISA Assay PublicationOPG ELISA Assay Publication
OPG ELISA Assay Publication
 
ICAD2008#2Final
ICAD2008#2FinalICAD2008#2Final
ICAD2008#2Final
 
Antibody Customer Review For Tau Polyclonal Antibody (STJ95911)
Antibody Customer Review For Tau Polyclonal Antibody (STJ95911)Antibody Customer Review For Tau Polyclonal Antibody (STJ95911)
Antibody Customer Review For Tau Polyclonal Antibody (STJ95911)
 
Poster congreso sevilla 2012
Poster congreso sevilla 2012Poster congreso sevilla 2012
Poster congreso sevilla 2012
 
AAPG5 Project 2
AAPG5 Project 2AAPG5 Project 2
AAPG5 Project 2
 
Lynch CERCA Poster S16 [4196]
Lynch CERCA Poster S16 [4196]Lynch CERCA Poster S16 [4196]
Lynch CERCA Poster S16 [4196]
 
Antiviral Agents
Antiviral AgentsAntiviral Agents
Antiviral Agents
 
Melanoma and Parkinson disease & Link between them.
Melanoma and Parkinson disease &  Link between them.Melanoma and Parkinson disease &  Link between them.
Melanoma and Parkinson disease & Link between them.
 
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
 
Aeha multipeptide and passive
Aeha multipeptide and passiveAeha multipeptide and passive
Aeha multipeptide and passive
 
Presentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014Presentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014
 
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchangeStructural basis of omalizumab therapy and omalizumab-mediated IgE exchange
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
 
AAPG5 Project 1
AAPG5 Project 1AAPG5 Project 1
AAPG5 Project 1
 
Ipbsgt06
Ipbsgt06Ipbsgt06
Ipbsgt06
 
Replacement Polymorphism of DENV E Asn-67 with Lys-67
Replacement Polymorphism of DENV E Asn-67 with Lys-67Replacement Polymorphism of DENV E Asn-67 with Lys-67
Replacement Polymorphism of DENV E Asn-67 with Lys-67
 

GCURS Presentation

  • 1. GCURS 2016 “The effect of modified PEG and GP100 on AuNV induced IL-12 production” Ángel A. Garcés, Emily Reiser Evans, Rebekah Drezek Drezek Lab October 22, 2016
  • 2. What is cancer immunotherapy? • Immune system recognizes foreign entities as harmful • After recognition, cytotoxic T-cells attack the entity and destroy it • Cancer cells difficult to recognize as foreign in the body • Retrain body to recognize cancer tumors and destroy them • Components of a successful vaccine: antigen and adjuvant
  • 3. Project Introduction • Developing gold nanoparticle (AuNP) vaccines (AuNV) for cancer immunotherapy applications in vitro in BMDCs • Specific antigen overexpressed in mouse melanoma tumors conjugated to AuNP induces immune response • Optimize the design of AuNVs for maximum effectiveness in vitro
  • 4. Specific project goals • To modify the GP100 peptide by replacing the terminal leucine residue with an aromatic one to induce a strong immune response • To quantify the immune response via IL-12 p70 ELISA
  • 5. Previous literature • Yang et. Al (2011): Aromatic amino acids conjugated to the end of AuNPs found to increase AuNV cellular uptake in vitro • Xia et. Al (2012): IL-12 crucial to maturation of CD8+ T-cells • Almeida et. Al (2015): AuNVs developed elicit successful immune responses in vivo via proof of concept antigen
  • 6. AuNV CD4+ AuNV activates APC CD8+ CD4+ recruits CD8+ cytotoxic T-cells Melanoma Tumor APC IL-12 cytokine secretion IL-12 Figure 1: Overview of AuNV immunology Antigen presenting cells (APCs), which represent either J774.A macrophages or BMDCs, produce cytokines to communicate with T-cells to coordinate an immune response. The more cytokines produced correlates to a stronger immune response.
  • 7. Modifying the GP100 peptide • Preliminary results: AuNP-PEG-GP100 showed highest induced IL-12 cytokine production in J774.A macrophages • GP100 had stronger immune response than other melanoma associated antigens • Unmodified GP100: KVPRNQDWL • Replaced end amino acid (“L”) with an aromatic amino acid Figure 2: Unmodified GP100 peptide structure The terminal Leucine has been highlighted for emphasis.
  • 8. GP100 Variant Amino Acid Sequence GP100 (Normal) KVPRNQDWL GP100 (W) KVPRNQDWW GP100 (Y) KVPRNQDWY GP100 (F) KVPRNQDWF GP100 (-L) KVPRNQDW- Table of GP100 variant sequences
  • 10. Results of preliminary ELISA testing -100 0 100 200 300 400 500 600 700 PBS AuNP-PEG (COOH) AuNP-PEG-GP100 (normal) AuNP-PEG-GP100 (W) AuNP-PEG-GP100 (Y) AuNP-PEG-GP100 (F) AuNP-PEG-GP100 (-L) LPS IL-12concentration(pg/mL) Preliminary AuNV induced IL-12 production observed in BMDCs in vitro
  • 11. Results of secondary ELISA testing 0 50 100 150 200 250 300 IL-12concentration(pg/mL) Secondary AuNV induced IL-12 production in vitro in BMDCs
  • 12. ELISA data analysis • Preliminary/secondary ELISA shows a significant immune response for PEGylated and GP100 variants • No discernable advantage to conjugating AuNVs with terminal aromatic residues; no discernable effect on IL-12 production • AuNP-PEG (COOH) induced higher IL-12 production than AuNP-mPEG • Terminal aromatic residues had no discernable effect on IL-12 production in BMDCs
  • 13. AuNP-PEG (COOH) vs. AuNP-mPEG AuNP AuNP
  • 14. Possible advantages to AuNP-PEG (COOH) • COO- group (at pH 7.4) is more hydrophilic than methyl group • PEG (COOH) has a net negative charge at physiological pH • Possibility for nucleophilic substitution to make covalent bonds arises • Kumar (2012): Covalent coupling to biological molecules • PEG (COOH) has a COO- similar to a C-terminus on proteins
  • 15. Conclusions • Terminal aromatic residues on AuNVs do not increase IL-12 production in BMDCs • Ability of AuNP-PEG (COOH) to covalently interact with cell receptors increases its applications for treating cancer
  • 16. Future directions • Further ELISA testing further confirm presence of PEG effects • Flow cytometry with anti-CD40, anti-CD86, and anti-CD80 cell surface markers to more accurately quantify immune response (paper?)

Editor's Notes

  1. Adjuvants stimulate the immune response to respond to the antigen of interest, but don’t provide immunity themselves (Wikipedia). One of adjuvant’s functions is to help present the antigen to the cells of interest, expose the body to the antigen over a long period of time. Basically helps your actual stuff “antigen” get to where it needs to go  Aluminum hydroxide is an example of an adjuvant for vaccines. Antigen: A molecule capable of inducing an immune response on a part of a host organism (Wikipedia boi). It causes the body to produce antibodies against something foregin inside of it. Antibodies match antigens!
  2. Introduce what I do very clearly. I make gold nanovaccines for use in vitro to retrain the natural immune response to recognize cancer tumors (the specific peptide on the thing) and destroy them.
  3. Use mainly as a transition slide. Objectives should be readily obvious but just make sure to emphasize it hard.
  4. Note in the Xia paper that CD8+ T cells are a type of th1 cell, which are the t cells that “attack” stuff in the body!
  5. Don’t forget to mention that we characterized the AuNVs with DLS and UV-Vis spec normally! BMDCs: Bone marrow derived cells (from femur of mice; dendritic cells) Mention the 3 day protocol for synthesizing gold nanovaccines very quickly  Note: Mice are B57BL6/J mice (naïve of course) Media is RPMI-1640; Growth factor is GCM ELISA is Quantikine IL-12 p70 ELISA
  6. This was the 06192016 ELISA run. Talk about how we initially saw that AuNP-Peg (cooh) was pretty huge. Decided from here to compare to AuNP-mPEG
  7. This is the 2nd “good” ELISA that we did back in September. Provides further proof that carboxylated peg is better than methylated peg for inducing the immune response  Exciting stuff
  8. Talk in detail about the differences between AuNP-PEG (COOH) and AuNP-mPEG No one GP100 variant was significantly better than the others. They are all over the place in terms of trends go Talk about how that our results on aromaticity that uptake does not necessarily correlate to activation of dendritic cells for the Th1 immune pathway
  9. Main difference between these two forms of PEG is CHARGE DIFFERENCES. Carboxylated PEG is negatively charged while methylated PEG is not charged at all. They both have the same chain length, chemical composition otherwise  Make sure to note that traditionally, PEG is in the mPEG form!
  10. Note that PEG in general helps to “hide” the nanoparticles from getting expelled by the RES (reticuloendothelial system), resists protein absorption Uptake mechanism isn’t too well known but Liu et al (2012) possibly thinks endocytosis mech bc they center around cytoplasm So… According to Kumar (2012); “the free carboxyl group… strongly participates in covalent coupling with various biological molecules by cross-linking to reactive amino acids.” COO- is similar to proteins which means that protein uptake mechanisms more likely to see it like that?